Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies

(2019) Xue-Ning Shen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease

(2019) Philip S. J. Weston et al.   Alzheimers Research & Therapy

Targeting Apolipoprotein E for Alzheimer’s Disease: An Industry Perspective

(2019) Georgette L. Suidan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Neurofilament light chain as a biomarker in neurological disorders

(2019) Lorenzo Gaetani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques

(2019) Carlo Sala Frigerio et al.   Cell Reports

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A)

(2019) Songye Li et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer’s disease

(2019) Sandra Sanabria Bohórquez et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Current and emerging avenues for Alzheimer's disease drug targets

(2019) R. Loera‐Valencia et al.   JOURNAL OF INTERNAL MEDICINE

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

(2019) Claire Bridel et al.   JAMA Neurology

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography

(2019) Niklas Mattsson et al.   JAMA Neurology

The neuropathological diagnosis of Alzheimer’s disease

(2019) Michael A. DeTure et al.   Molecular Neurodegeneration

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study

(2019) Andre Mueller et al.   JOURNAL OF NUCLEAR MEDICINE

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

(2019) Maria João Leitão et al.   Alzheimers Research & Therapy

Plasma biomarkers of astrocytic and neuronal dysfunction in early‐ and late‐onset Alzheimer's disease

(2019) Fanny M. Elahi et al.   Alzheimers & Dementia

Cortical Microstructural Alterations in Mild Cognitive Impairment and Alzheimer’s Disease Dementia

(2019) Nicholas M Vogt et al.   CEREBRAL CORTEX

Advances and considerations in AD tau-targeted immunotherapy

(2019) Alice Bittar et al.   NEUROBIOLOGY OF DISEASE

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology

(2018) Erik Portelius et al.   ACTA NEUROPATHOLOGICA

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

(2018) Ron Brookmeyer et al.   Alzheimers & Dementia

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

(2018) John L Robinson et al.   BRAIN

In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer’s disease dementia to young controls

(2018) Tobey J Betthauser et al.   JOURNAL OF NUCLEAR MEDICINE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging

(2018) Ming-Kai Chen et al.   JAMA Neurology

Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools

(2018) Silvia Paciotti et al.   Frontiers in Neurology

Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

(2018) Bradley R. Groveman et al.   Acta Neuropathologica Communications

Evaluation of18F-RO-948 (18F-RO6958948) for quantitative assessment of tau accumulation in the human brain with positron emission tomography

(2018) Hiroto Kuwabara et al.   JOURNAL OF NUCLEAR MEDICINE

Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers

(2018) Cristian C. Constantinescu et al.   MOLECULAR IMAGING AND BIOLOGY

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Current state of Alzheimer’s fluid biomarkers

(2018) José Luis Molinuevo et al.   ACTA NEUROPATHOLOGICA

The glymphatic pathway in neurological disorders

(2018) Martin Kaag Rasmussen et al.   LANCET NEUROLOGY

Biomarkers for tau pathology

(2018) Michael Schöll et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease

(2018) Ann D. Cohen et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

New insights into the role of TREM2 in Alzheimer’s disease

(2018) Maud Gratuze et al.   Molecular Neurodegeneration

Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease

(2018) Miia Kivipelto et al.   Nature Reviews Neurology

Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury

(2017) Tanya Bogoslovsky et al.   JOURNAL OF NEUROTRAUMA

Tau PET imaging: present and future directions

(2017) Laure Saint-Aubert et al.   Molecular Neurodegeneration

[18F]FDG PET signal is driven by astroglial glutamate transport

(2017) Eduardo R Zimmer et al.   NATURE NEUROSCIENCE

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease

(2017) Joana B. Pereira et al.   NEUROBIOLOGY OF AGING

Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers

(2017) Kaitlin B. Casaletto et al.   NEUROLOGY

Review: Tau in biofluids - relation to pathology, imaging and clinical features

(2017) H. Zetterberg   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

(2017) Kok Pin Ng et al.   Alzheimers Research & Therapy

Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid

(2017) Mohammad Shahnawaz et al.   JAMA Neurology

TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia

(2016) Bryan D. James et al.   BRAIN

The Cellular Phase of Alzheimer’s Disease

(2016) Bart De Strooper et al.   CELL

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

(2016) Marc Suárez‐Calvet et al.   EMBO Molecular Medicine

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

(2016) Stephen P. Arnerić et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease

(2016) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

Altered Proteins in the Aging Brain

(2016) Adila Elobeid et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Increased CSF neurogranin concentration is specific to Alzheimer disease

(2016) Henrietta Wellington et al.   NEUROLOGY

Tauopathies as clinicopathological entities

(2016) David J. Irwin   PARKINSONISM & RELATED DISORDERS

Early changes in CSF sTREM2 in dominantly inherited Alzheimers disease occur after amyloid deposition and neuronal injury

(2016) M. Suarez-Calvet et al.   Science Translational Medicine

Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies

(2016) Graham Fairfoul et al.   Annals of Clinical and Translational Neurology

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

(2015) Hlin Kvartsberg et al.   Alzheimers & Dementia

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

(2015) Ann De Vos et al.   Alzheimers & Dementia

Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

(2015) Tobias Skillbäck et al.   BRAIN

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education

(2013) Keith A. Johnson et al.   Alzheimers & Dementia

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Biomarker Modeling of Alzheimer’s Disease

(2013) Clifford R. Jack et al.   NEURON

Quantification of α-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?

(2013) Brit Mollenhauer   PARKINSONISM & RELATED DISORDERS

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

Age and diagnostic performance of Alzheimer disease CSF biomarkers

(2012) N. Mattsson et al.   NEUROLOGY

Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study

(2012) Jeffrey Randall et al.   RESUSCITATION

An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28

(2011) David R Owen et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

The Translocator Protein

(2011) A. M. Scarf et al.   JOURNAL OF NUCLEAR MEDICINE

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

(2011) Eric M. Reiman   NEUROBIOLOGY OF AGING

Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults

(2011) B. C. Dickerson et al.   NEUROLOGY

The clinical use of structural MRI in Alzheimer disease

(2010) Giovanni B. Frisoni et al.   Nature Reviews Neurology

Acceleration of hippocampal atrophy in a non-demented elderly population: the SNAC-K study

(2009) Yi Zhang et al.   INTERNATIONAL PSYCHOGERIATRICS